Literature DB >> 23303071

Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors.

S A Neale1, C S Copeland, V N Uebele, F J Thomson, T E Salt.   

Abstract

Xanthurenic acid (XA), an endogenous kynurenine, is a known vesicular glutamate transport (VGLUT) inhibitor and has also been proposed as an mGlu2/3 receptor agonist. Changes in these systems have been implicated in the pathophysiology of schizophrenia and other psychiatric disorders; however, little is known of how XA affects synaptic transmission. We therefore investigated the effects of XA on synaptic transmission at two hippocampal glutamatergic pathways and evaluated the ability of XA to bind to mGlu2/3 receptors. Field excitatory postsynaptic potentials (fEPSPs) were recorded from either the dentate gyrus (DG) or CA1 region of mouse hippocampal slices in vitro. Addition of XA to the bathing medium (1-10 mM) resulted in a dose-related reduction of fEPSP amplitudes (up to 52% reduction) in both hippocampal regions. In the DG, the VGLUT inhibitors Congo Red and Rose Bengal, and the mGlu2/3 agonist LY354740, also reduced fEPSPs (up to 80% reduction). The mGlu2/3 antagonist LY341495 reversed the LY354740 effect, but not the XA effect. LY354740, but not XA, also reduced DG paired-pulse depression. XA had no effect on specific binding of 1 nM [(3)H]LY341495 to membranes with human mGlu2 receptors. We conclude that XA can modulate synaptic transmission via a mechanism that may involve VGLUT inhibition rather than activation of mGlu2/3 receptors. This could be important in the pathophysiology of nervous system disorders including schizophrenia and might represent a target for developing novel pharmacological therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303071      PMCID: PMC3629405          DOI: 10.1038/npp.2013.4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  49 in total

1.  Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice.

Authors:  James N C Kew; Marie-Claire Pflimlin; John A Kemp; Vincent Mutel
Journal:  Neuropharmacology       Date:  2002-08       Impact factor: 5.250

2.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect.

Authors:  I P Lapin; G F Oxenkrug
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

3.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.

Authors:  S Erhardt; K Blennow; C Nordin; E Skogh; L H Lindström; G Engberg
Journal:  Neurosci Lett       Date:  2001-11-02       Impact factor: 3.046

4.  Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport.

Authors:  Christina N Carrigan; Richard D Bartlett; C Sean Esslinger; Kimberly A Cybulski; Pakamas Tongcharoensirikul; Richard J Bridges; Charles M Thompson
Journal:  J Med Chem       Date:  2002-05-23       Impact factor: 7.446

5.  Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia.

Authors:  R E Smith; V Haroutunian; K L Davis; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

Review 6.  Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai; Donald Goff
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

7.  An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size.

Authors:  S M Wojcik; J S Rhee; E Herzog; A Sigler; R Jahn; S Takamori; N Brose; C Rosenmund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

8.  Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites.

Authors:  Robert T Fremeau; Kaiwen Kam; Tayyaba Qureshi; Juliette Johnson; David R Copenhagen; Jon Storm-Mathisen; Farrukh A Chaudhry; Roger A Nicoll; Robert H Edwards
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

9.  Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice.

Authors:  I P Lapin
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 10.  Molecular pharmacology of glutamate transporters, EAATs and VGLUTs.

Authors:  Yasushi Shigeri; Rebecca P Seal; Keiko Shimamoto
Journal:  Brain Res Brain Res Rev       Date:  2004-07
View more
  21 in total

1.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

2.  Xanthurenic Acid Formation from 3-Hydroxykynurenine in the Mammalian Brain: Neurochemical Characterization and Physiological Effects.

Authors:  K V Sathyasaikumar; M Tararina; H-Q Wu; S A Neale; F Weisz; T E Salt; R Schwarcz
Journal:  Neuroscience       Date:  2017-10-12       Impact factor: 3.590

3.  Changes in serum levels of kynurenine metabolites in paediatric patients affected by ADHD.

Authors:  Melania Evangelisti; Pietro De Rossi; Jole Rabasco; Renato Donfrancesco; Luana Lionetto; Matilde Capi; Gabriele Sani; Maurizio Simmaco; Ferdinando Nicoletti; Maria Pia Villa
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-05-19       Impact factor: 4.785

4.  Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Supaksorn Thika; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Cristiano Noto; Rada Ivanova; Michael Maes
Journal:  Metab Brain Dis       Date:  2017-03-03       Impact factor: 3.584

Review 5.  Glutamate Release.

Authors:  John T Hackett; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2015-05-27       Impact factor: 3.996

Review 6.  Kynurenines and Glutamate: Multiple Links and Therapeutic Implications.

Authors:  R Schwarcz
Journal:  Adv Pharmacol       Date:  2016-03-11

Review 7.  VGLUTs in Peripheral Neurons and the Spinal Cord: Time for a Review.

Authors:  Pablo R Brumovsky
Journal:  ISRN Neurol       Date:  2013-11-20

Review 8.  Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology.

Authors:  Jennifer M Parrott; Jason C O'Connor
Journal:  Front Psychiatry       Date:  2015-08-20       Impact factor: 4.157

9.  Altered serum levels of kynurenine metabolites in patients affected by cluster headache.

Authors:  Martina Curto; Luana Lionetto; Andrea Negro; Matilde Capi; Francesca Perugino; Francesco Fazio; Maria Adele Giamberardino; Maurizio Simmaco; Ferdinando Nicoletti; Paolo Martelletti
Journal:  J Headache Pain       Date:  2016-03-22       Impact factor: 7.277

10.  Altered kynurenine pathway metabolites in serum of chronic migraine patients.

Authors:  Martina Curto; Luana Lionetto; Andrea Negro; Matilde Capi; Francesco Fazio; Maria Adele Giamberardino; Maurizio Simmaco; Ferdinando Nicoletti; Paolo Martelletti
Journal:  J Headache Pain       Date:  2016-04-29       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.